Supplementary

Supplementary Figure 1, Trial Design
Guidelines for insulin dose titration in the CIMT trial (translated from the Danish version used in the trial).
The therapeutic goal is near-normalisation of HbA1c ≤7.0% taking the individual risk of hypoglycaemia into account.
The following algorithms are guidelines supporting the titration of insulin dose. It is at the investigators discretion to individual assessments.
Optimal therapeutic goal of fasting, pre-prandial and bedtime plasma glucose is <5.5 mmol/L.
It is at the investigators discretion to evaluate when the individual optimal insulin treatment is reached since the therapeutic goal might not be reachable in all participants.
After the initial titration all participants shall on a daily basis measure fasting plasma glucose and plasma glucose before insulin injections.
During the first 12 weeks of the trial, it is recommended that all participants have weekly telephone contact with the study nurse in order to discuss plasma glucose measurements, hypoglycaemic episodes and insulin titration. Subsequently, telephone contact is recommended every two to three weeks at the investigators discretioInsulin titration guideline for insulin Levemir® once daily (bedtime).
Initial dose of insulin in insulin naïve participants at trial entry is 0.2 IU/kg/day with injection in the thigh before bedtime.
Patients with insulin treatment at trial entry continue with insulin Levemir® 1:1 IU compared to the prior daily insulin dose .
Plasma glucose is measured daily before breakfast. The lowest measured plasma glucose is used to adjust insulin dose every third day according to the following:
If one plasma glucose measure is ≤ 3.0 mmol/L the participant shall contact the study nurse or investigator in order to adjust insulin dose.
Goal is a fasting plasma glucose <5.5 mmol/L Patients with insulin treatment at trial entry continue with insulin NovoMix 30® 1:1 E compared to the prior daily insulin dose .
If one plasma glucose measure is ≤ 3.0 mmol/L, the participant shall contact the study nurse or investigator in order to adjust insulin dose.
Goal is a fasting plasma glucose <5.5 mmol/L.
B. Introduction of a second dose of NovoMix 30®
When fasting plasma glucose is <5.5 mmol/L, before-dinner plasma glucose is measured.
If before-dinner plasma-glucose is >5.5 mmol/L, a second dose of 0.2 IU/kg NovoMix 30® is added in the morning.
Plasma glucose is measured daily before dinner. The lowest measured plasma glucose is used adjust insulin dose every third day according to the following: Goal is a plasma glucose before dinner <5.5 mmol/L.
C. Introduction of a third dose of NovoMix 30®
If the therapeutic goal (defined as HbA1c<7.0%) is not reached with NovoMix 30® twice daily during the first three months, a third dose of 0.2 IU/kg NovoMix 30® is added before lunch.
Plasma glucose is measured daily before bedtime. The lowest measured plasma glucose is used adjust insulin dose every third day according to the following:
Goal is a plasma glucose before bedtime <5.5 mmol/L.
* Several previous studies have successfully titrated premixed insulin in patients with type 2 diabetes based on only fasting blood glucose levels to titrate insulin dose before dinner, and pre-dinner glucose to titrate the morning insulin dose, and in some patients also the lunchtime insulin dose (Lund et al, BMJ 2009). The major regulator of glycaemic control when using biphasic insulin is the long acting insulin component (70% of the insulin dose), which explains the use of the mentioned time points for glucose monitoring
Bedtime Levemir® in combination with Novorapid® before main meals
Initial dose of insulin in insulin naïve participants at trial entry is Levemir® 0.2 IU/kg/day with injection in the thigh before bedtime.
Patients with insulin treatment at trial entry continue with a daily dose of insulin Levemir® 1:1 E compared to the prior daily insulin dose .
50% of the total dose of insulin is injected as prandial insulin NovoRapid® and 50% is injected as bedtime Levemir®. The prandial insulin is injected as 35+30+35% before the three main meals taking individual eating habits into account.
The principle in the algorithm is initially to regulate fasting plasma glucose and subsequently pre-prandial and bedtime plasma glucose levels. In this treatment regimen it is possible to treat post-prandial plasma glucose increase. The post-prandial plasma glucose levels should be regulated when the pre-prandial levels are optimised.
Plasma glucose Adjustment of insulin dose
Plasma glucose is measured daily before breakfast. The lowest measured plasma glucose is used adjust insulin dose Levemir® at bedtime every third day according to the following:
B. Regulation of pre-prandial and bedtime plasma glucose levels.
Plasma glucose is regulated in the following order: before lunch, before dinner and bedtime according to the following:
Plasma glucose is measured daily before main meals and before bedtime. The lowest measured plasma glucose is used to titrate insulin NovoRapid® before the previous meal every third day according to the following:
If one plasma glucose measure is ≤ 3.0 mmol/L the participant shall contact the study nurse or investigator in order to adjust insulin dose. Plasma glucose is regulated in the following order: after breakfast, after lunch, after dinner according to the following:
Plasma glucose
Plasma glucose is measured daily one hour after meals. The dose of NovoRapid® before the previous meal is regulated every third day according to the following:
Goal is a plasma glucose one hour after meals < 7 mmol/L.
Plasma glucose Adjustment of insulin dose
Mean PG < 4 mmol/L -2 IU Two or more measures > 7 mmol/L + 2 IU
